ClinicalTrials.gg
Not yet recruitingNCT06320912Updated Mar 20, 2024

Efficacy and Safety of Intraparenchymal Portal Vein Covered Stents in Treating Portal Hypertension and Its Complications

An interventional study of The intraparenchymal portal vein covered stent and TIPS Covered Stent System GORE in Portal Hypertension, sponsored by Shanghai Shenqi Medical Technology Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-20.

Sponsored by Shanghai Shenqi Medical Technology Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Hypertension, Portal with a site in China — 38 open to participants now, 40 under way, none of them phase 3. Hypertension, Portal · China.

Planned enrollment
5th of 64
258 · median 100
Started
2024
with 6 others
No phase
45 of 106
16 open now
Primary completion
2026-06
later than 13 of 39 live
Registered
81st of 106
by date

Among the 106 studies in Hypertension, Portal with a site in China, this one is the 5th largest by planned enrollment of the 64 interventional ones that give a count, is one of 7 that started in 2024, is one of 45 with no phase, reaches primary completion later than 13 of the 39 other live ones, and was the 81st registered.

Hypertension, Portal

376 studies on the registry are indexed under Hypertension, Portal; 114 are open to participants now.

Browse Hypertension, Portal studies →

Open to participants now

38 of the 106 studies in Hypertension, Portal with a site in China are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 68 Hypertension, Portal studies recruiting now, 33 (49%) set no upper age limit and 12 (18%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Hypertension, Portal with a site in China, or all of them as a file.
02

Study summary

The objective of this study is to assess the non-inferiority of the intraparenchymal portal vein covered stent in terms of safety and efficacy for managing portal hypertension and its related complications, in comparison to the currently available TIPS Covered Stent System by GORE.

Read the detailed description

This study is a prospective, multicenter, randomized controlled, non-inferiority clinical trial. It plans to enroll approximately 258 qualified participants from about 25 research centers nationwide. Participants will be randomly assigned in a 1:1 ratio to either the experimental group or the control group for the treatment of portal hypertension and its related complications. The primary endpoint of the study is the patency rate of the stents 12 months after the initial surgery. All participants will undergo clinical follow-ups at 1 month, 6 months, and 1 year post-stent implantation.

03

Conditions studied

  • Portal Hypertension

Browse trials for

Keywords

  • Portal hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years (inclusive); male or non-pregnant female.
  • Diagnosed with cirrhosis and associated complications of portal hypertension (such as esophageal and gastric variceal bleeding, ascites), and meeting the consensus recommendations for TIPS indications (see Appendix 5).
  • Participants must understand the purpose of the trial, voluntarily participate, sign an form, and be willing to complete the follow-up according to the project requirements.

Exclusion criteria

Exclusion Criteria:

  • Severe right heart failure, congestive heart failure ( \< 40%), or severe valvular heart dysfunction.
  • Uncontrolled systemic infection or inflammation.
  • Persistent moderate to severe pulmonary hypertension after treatment (tricuspid regurgitant peak velocity > 3.4 m/s or pulmonary artery systolic pressure > 50 mmHg).
  • Patients in hepatic encephalopathy coma or comatose phase (West Haven Criteria Stage III, IV).
  • Severe liver dysfunction, score > 13, or MELD score > 18.
  • Serum creatinine (Scr) > 178 umol/L or on dialysis.
  • Stage IIIa or higher liver .
  • Budd-Chiari syndrome, hepatic veno-occlusive disease, or obstructive cholestasis.
  • Polycystic liver disease.
  • Unrectifiable coagulopathy ( > 5 or count \< 20 x 10\^9/L).
  • Main portal vein thrombosis occupying > 50% of the lumen area or cavernous transformation of the portal vein.
  • Previous TIPS procedure or planned liver transplantation within a year.
  • Allergy to contrast agents or nickel-titanium alloys.
  • less than 1 year.
  • Participation in other drug or medical device clinical trials within three months before screening.
  • Other conditions deemed by the researcher as unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
258 participants (estimated)

Study arms

  • Experimental
    Group(A)

    Device: The intraparenchymal portal vein covered stent

  • Active comparator
    Group(B)

    Device: TIPS Covered Stent System GORE

Interventions

  • DeviceThe intraparenchymal portal vein covered stent

    The intraparenchymal portal vein covered stent, produced by Shanghai Shenqi Medical Technology Co., Ltd., is used for a transjugular approach. It establishes an artificial shunt between the hepatic vein and the main branches of the portal vein within the liver. This helps in reducing portal venous pressure and alleviating or improving the symptoms of portal hypertension and its complications, such as variceal bleeding, gastropathy, refractory ascites, and/or hepatic hydrothorax.

  • DeviceTIPS Covered Stent System GORE

    The GORE® VIATORR® Transjugular Intrahepatic Portosystemic Shunt (TIPS) Covered Stent consists of an implantable covered stent and a percutaneous delivery catheter.

06

What researchers measure

Primary outcomes

  1. Postoperative Stent Patency Rate

    In the absence of a secondary intervention, portal venography indicates a luminal narrowing of ≤50% and a portal pressure gradient (PPG) of ≤12mmHg or a reduction of ≥50% from the baseline value prior to the surgery.

    Time frame: 12 months

Secondary outcomes

  1. Immediate Postoperative Technical Success Rate

    Successful insertion and smooth withdrawal of the covered stent and delivery system, successful establishment of a shunt, accurate positioning of the stent, and postoperative angiography showing ≤30% diameter narrowing.

    Time frame: Immediate postoperative

  2. Incidence of Secondary Interventions at 1 Month, 6 Months, and 12 Months Postoperatively

    Time frame: 1 Month, 6 Months, and 12 Months

  3. Incidence of Stent Dysfunction at 1 Month, 6 Months, and 12 Months Postoperatively

    Time frame: 1 Month, 6 Months, and 12 Months

  4. Incidence of Major Adverse Events (MAE) at 1 Month, 6 Months, and 12 Months Postoperatively

    Time frame: 1 Month, 6 Months, and 12 Months

  5. All-Cause Mortality Rates at 1 Month, 6 Months, and 12 Months Postoperatively

    Time frame: 1 Month, 6 Months, and 12 Months

  6. Incidence of Grade II or Higher Hepatic Encephalopathy at 1 Month, 6 Months, and 12 Months Postoperatively

    Time frame: 1 Month, 6 Months, and 12 Months

  7. Incidence of Portal Hypertension Rebleeding Confirmed by Endoscopy or Clinical Investigator at 1 Month, 6 Months, and 12 Months Postoperatively (For Original Bleeding Subjects Only)

    Time frame: 1 Month, 6 Months, and 12 Months

  8. Incidence of Ultrasound-Confirmed Recurrence of Grade 2 or Higher Ascites due to Portal Hypertension at 1 Month, 6 Months, and 12 Months Postoperatively (For Subjects with Original Ascites Only)

    Time frame: 1 Month, 6 Months, and 12 Months

  9. Incidence of Adverse Events/Serious Adverse Events

    Time frame: 12 Months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2024; primary completion for Jun 2026, 25 months later.

Of 61 interventional studies with no phase under Hypertension, Portal, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 72. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2024
First posted
Mar 20, 2024
StartEst.
Apr 5, 2024
Primary completionEst.
Jun 1, 2026
CompletionEst.
Nov 1, 2026
Last update
Mar 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06320912
Lead sponsor
Shanghai Shenqi Medical Technology Co., Ltd
Responsible party
Sponsor
First posted
Mar 20, 2024
Start date
Apr 5, 2024 (estimated)
Primary completion
Jun 1, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Mar 20, 2024

Study contacts

chaojun gu
Contact
chaojun.gu@sqmedical.com
+86-13636491192

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion